Current status of MitraClip for patients with mitral and tricuspid regurgitation

Sidakpal S. Panaich, Mackram Eleid

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

Mitral valve regurgitation (MR) affects approximately 4 million people in the United States alone, increasing in prevalence with age. Approved by the Food and Drug Administration (FDA) in October 2013, percutaneous edge-to-edge transcatheter mitral valve repair (also known as the MitraClip system) has been used in over 40,000 patients globally. Additionally, there is keen interest and early exploration into the use of MitraClip for treatment of severe symptomatic tricuspid regurgitation, another undertreated disease with significant morbidity and mortality. In this manuscript, we aim to review the current indications, procedural details as well as emerging indications for this novel technology.

Original languageEnglish (US)
Pages (from-to)200-209
Number of pages10
JournalTrends in cardiovascular medicine
Volume28
Issue number3
DOIs
StatePublished - Apr 1 2018

    Fingerprint

Keywords

  • MitraClip
  • mitral regurgitation
  • transcatheter repair
  • tricuspid regurgitation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this